Rhys Williams, JD, MBA
Prior to co-founding iTherapeutics, Mr. Williams served as the CEO of Tequesta BioScience, which developed therapeutic applications from marine natural products, and of StromaCyte, which focused upon immune system reconstitution via thymic regeneration. His prior business experience includes roles as a Venture Capitalist with SI Ventures, finance and legal executive for Ixion Biotechnology, and professional/management roles with Smith Barney, American Express, and the U.S. Army Special Operations. He holds an MBA and a law degree from the University of Florida, and an undergraduate degree from Harvard magna cum laude. He is also Chairman of the South Florida Science Museum and President of New World Angels, Inc., a statewide angel investor group.
George Inana, MD, PhD
Dr. Inana is a co-inventor on the Company’s core patent, as well as Professor of Ophthalmology and the Director of the Laboratory of Molecular Genetics at the top-ranked Bascom Palmer Eye Institute, at the University of Miami. He is a leading researcher in the field of retinal degeneration, having cloned the first gene for inherited retinal degeneration in 1986, with extensive publications in the field. He is a Phi Beta Kappa graduate of Johns Hopkins University and received both an MD and a PhD degree in Biochemistry from the University of Chicago, and performed his residency in pathology at the Stanford University Hospital. He completed his post-doctoral training at the National Institute of Health, where he became the Head of Molecular Pathology Section.
Margaret McClaren, JD, PhD
Chief Legal Counsel
Dr. McLaren is co-inventor / author of the Company’s core patent. She has over 20 years of research experience in cell and molecular biology of RPE, the tissue affected in AMD, having held academic positions at medical schools in Canada and most recently at Bascom Palmer Eye Institute. She is also a registered patent attorney and presently practices as founder of the Life Sciences practice group for the law firm of Carey Rodriguez Greenberg & Paul LLP. She received a law degree from the University of Miami cum laude, a Ph.D. (Dean’s List), a Masters Degree in Anatomy from McGill University, and an undergraduate degree in Biology with honors from the University of Toronto.
Claes Wahlestedt, MD, PhD
Chief Technology Officer
Dr. Wahlestedt is a professor and the Director of Neuroscience Discovery for The Scripps Research Institute at Scripps Florida. He is internationally recognized as a top researcher in the field of pharmacological treatments for nervous disorders, and has authored more than 150 papers in major scientific journals in his field. He served as the founding director of the Center for Genomics and Bioinformatics at the Karolinska Institute in Stockholm, Sweden. He received both his medical degree and Ph.D. from Lund University in Sweden. He did postdoctoral work at the Georgetown Institute of the Neurosciences at Georgetown University in Washington, D.C. and at the Institute for Immunology at Kyoto University, Japan. He then spent four years as assistant professor in the Division of Neurobiology, Department of Neurology and Neuroscience at Cornell University Medical College in New York, and was subsequently adjunct professor of biochemistry, and pharmacology and therapeutics at McGill University, Montreal. He has held senior leadership team positions in the R&D organizations of Astra-Zeneca as well as Pharmacia/Pfizer.